Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
- Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North America
- Ustekinumab is a fully human monoclonal antibody to interleukin (IL)-12/23, approved for treatment of plaque psoriasis, psoriatic arthritis, Crohn´s disease and ulcerative colitis
- Deal further strengthens Sandoz position in immunology and supports further pipeline expansion
Basel, September 11, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today announced that it has entered into a development and commercialization agreement with Samsung Bioepis.
The agreement provides Sandoz with the exclusive rights to commercialize the biosimilar SB17 ustekinumab in the US, Canada, EEA, Switzerland, and UK. Other specific terms of the agreement are confidential.
“This deal represents another major step to reinforce our high-value biosimilar pipeline, in line with our plans to become a standalone global leader,” says Sandoz CEO Richard Saynor. “It will further strengthen our immunology patient offering and means we now have five potential high-value upcoming biosimilar launches over the next few years.”
The reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders including Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
Psoriasis is a chronic inflammatory disease of the skin and other parts of the body, which affects 60 million people worldwide1. Psoriasis has a huge impact on patients´ quality of life (QoL) and has a substantial economic burden, with annual mean costs of up to EUR 11,928 per patient globally2.
Inflammatory bowel diseases (Crohn´s disease and ulcerative colitis) are chronic gastrointestinal disorders that affect more than 3 million people in Europe and in the US3, with a high associated economic burden and annual direct costs of up to 6 bn in Europe4 and 25.4 bn USD5 in the USA. IBD negatively impacts patients’ quality of life by affecting daily activities, work ability and social life6.
The clinical development program for SB17, a ustekinumab biosimilar, is well advanced and Phase I results were presented at the American Academy of Dermatology (AAD) Annual Meeting held in New Orleans, US, in March 2023 by Samsung Bioepis. This study demonstrated that SB17 matches reference ustekinumab in terms of pharmacokinetic (PK) bioequivalence, safety, tolerability, and immunogenicity.. SB17 Phase III clinical study results will be presented at a medical congress later this year.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
- https://www.globalpsoriasisatlas.org/en/explore (accessed August 2023).
- Jungen D et al. Cost-of-illness of psoriasis—results of a German cross-sectional study. J Eur Acad Dermatol Venereol. 2018;32:174–80
- Lancet Gastroenterol Hepatol 2020; 5: 17–30.
- Burisch J. et al. The burden of inflammatory bowel disease in Europe, Journal of Crohn's and Colitis, Volume 7, Issue 4, May 2013, P. 322–337
- Singh S et al. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. Inflamm Bowel Dis. 2022 Mar 2;28(3):364-372.
- Pulley J et al. Malnutrition and quality of life among adult inflammatory bowel disease patients.. JGH Open. 2020;4:454–460
# # #
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our vision is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines covers major therapeutic areas.
Sandoz on social media:
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/
# # #
|Sandoz Global Communications|
|Chris Lewis||+49 174 244 9501||Leslie Pott||+1 609 627 5287|
|Novartis Media Relations|
|Richard Jarvis||+41 79 584 2326||Julie Masow||+1 862 579 8456|
|Satoshi Sugimoto||+41 79 619 2035|
|Novartis Investor Relations|
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 345 4440|
|Nicole Zinsli-Somm||+41 61 324 3809||Parag Mahanti||+1 973 876 4912|
|Isabella Zinck||+41 61 324 7188|
STELARA® (ustekinumab) injection, for subcutaneous or intravenous (fda.gov) accessed 05 Jun 2023
Stelara | European Medicines Agency (europa.eu) accessed 05 Jun 2023
Stelara, INN-ustekinumab (europa.eu) accessed 05 Jun 2023
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote
Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release
Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla
Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release
29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the
Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel